Multiple myeloma (MM) remains an incurable malignancy as a result of innate drug resistance at diagnosis. 1 Highdose chemoradiotherapy with either autologous or allogeneic stem cell transplantation has been widely used during the last decade and may improve long-term survival. [2] [3] [4] Allogeneic BMT, in particular, is attractive because it provides the opportunity to exploit the antitumor effect of the marrow graft as an adoptive immunotherapy against residual tumor cells. This immunologic component, referred to as the graft-versus-tumor (GVT) effect, is mediated by immunocompetent donor leukocytes contained in the transplanted marrow. [5] [6] [7] Recently, the existence of a graft-versus-myeloma (GVM) effect was indicated by studies documenting remissions after donor leukocyte infusions (DLIs) in patients with relapsed multiple myeloma following allogeneic BMT. [8] [9] [10] [11] [12] [13] However, the highly beneficial effects of GVM are often offset by the occurrence of severe graft-versus-host disease (GVHD). 9 The induction of tumor-specific T cell reactivity may allow separation of GVM effects from GVHD.
Idiotypic immunoglobulin can be used as a tumorspecific antigen, since idiotype determinants are restricted markers for B cell lymphomas including MM. Based on experimental studies showing that immunization with tumor-derived Ig can generate effective anti-idiotype immune responses against several B cell tumor models, [14] [15] [16] [17] clinical trials using id-vaccination strategies in patients with B cell lymphomas, such as follicular lymphoma (FL) or multiple myeloma were performed. Whereas in FL id-vaccination can produce clinical responses, beneficial effects in myeloma patients are scarce. [18] [19] [20] [21] In the allogeneic setting Kwak et al 22 were the first to describe that idiotype protein-specific immunity can be transferred from bone marrow transplant donor to the multiple myeloma recipient. In a murine transplant model the same investigators were able to show that vaccination of the allogeneic donor with the B cell lymphoma idiotype can induce antitumor protection against an otherwise lethal tumour challenge in the recipient. 23 However, no significant long-term survival could be achieved in this model.
The objective of the present study was to perform donor vaccination studies in a newly established murine myeloma model. We show that potent GVM effects can be elicited by idiotype-primed marrow grafts. These antimyeloma effects could be further enhanced after additional transfer of immune splenocytes given shortly post transplant. Furthermore, we demonstrate that donor-type CD8 ϩ T cells play a critical role in eliminating residual myeloma cells.
Materials and methods

Animals
Balb/c (H-2 d ) and DBA/2 (H-2 d ) mice were bred and kept at the animal facilities of our institute. All animals were housed in conventional cages, seven to 10 animals per cage, and were given non-sterilized food and water ad libitum. Cotrimoxazole was added to the water for 40 days after bone marrow transplantation. YAC-1 cells were used as a NK-sensitive target in a 51 Cr-release assay. The cells were continuously maintained in culture with RPMI 1640 and 5% fetal calf serum (FCS) at 37°C and 5% CO 2 .
Peptides HOPC-1F immunoglobulin was obtained from Sigma (Heidelberg, Germany), the control immunoglobulin, Orthoclone OKT3, was obtained from Janssen-Cilag (Neuss, Germany). For vaccination studies the complete immunoglobulin was used.
Tumor diagnosis
Animals were examined daily and necropsied after death. Animals dying of myeloma exhibit bulky abdominal tumors with malignant ascites.
Assessment of GVHD
Survival of transplanted animals was followed to day 180 after BMT. Body weights were taken on the day of transplantation and then every 10 days. Death due to GVHD was defined as death with macroscopic signs of GVHD such as weight loss, rough fur, hair loss, and gibbus. In some mice with overt GVHD histological examination of skin and liver was performed which always revealed changes compatible with acute GVHD.
Conditioning and bone marrow transplantation
A 137 Cs source was used for total body irradiation (TBI). 7.5 Gy of TBI was defined as the lethal dose for allogeneic BMT. Bone marrow was collected by flushing the femurs and tibias with RPMI 1640. A single cell suspension was prepared by passing the BM cells through a nylon mesh.
Spleen cell preparation
To obtain MHC-identical (H-2 d ) donor lymphocytes differing in minor antigens, DBA/2 mice were killed under ether anesthesia. The spleens were removed and pressed through wire mesh screens to obtain single cell suspensions. Mononuclear cells were isolated by gradient centrifugation (Lympholyte; Cedarlane, Ontario, Canada), washed twice with RPMI, and appropriately resuspended in RPMI ϩ 5% FCS.
Immunophenotyping
For marker analysis spleen cells were incubated with appropriate primary and secondary antibodies and analyzed using a flow cytometer (FACScan; Becton Dickinson, Mountain View, CA, USA). The following antibodies were used: anti-CD3 (KT3), anti-CD8 (KT15), anti-CD4 (RM4-4), antiThy1.2 (30-H12), anti-NK (5E6), Pan NK (DX5) and anti-CD19 (1D3). With two exceptions, all monoclonal antibodies were obtained from Pharmingen (San Diego, CA, USA); anti-CD3 (KT3) and anti-CD8 (KT15) antibodies were obtained from Serotec (Wiesbaden, Germany). 
Experimental design
Immunization protocol
Healthy DBA donors were treated with three weekly injections (i.p.) of 50 g HOPC-1F-IgG 2a or the same dose of the control protein given with incomplete Freund's adjuvant (IFA; Sigma, 50 l IFA mixed with 50 l protein). Seven days after the last vaccination, marrow grafts were harvested for BMT.
CTL assay
DBA donors received the vaccination protocol, as described above. Seven days after the last vaccination, animals were killed under ether anesthesia. The spleens were removed and pressed through wire mesh screens to obtain single cell suspensions. Mononuclear cells were isolated by density gradient centrifugation (Lympholyte). Afterwards, splenocytes were restimulated in 24-well plates at a concentration of 5 ϫ 10 6 cells/ml with 1 ϫ 10 6 irradiated (30 Gy) HOPCmyeloma cells. After 5 days, viable cells (in some experiments primed splenocytes were enriched for CD4 and CD8 ϩ T cells) were harvested and tested in a
51
Cr release assay for their ability to lyse HOPC myeloma cells.
Cytotoxicity assay
Effector cells were prepared by density gradient centrifugation of spleen cell suspensions as described above. Target cells were obtained from cell culture and were labeled with 200 Ci of NaCrO 4 (Amersham-Buchler, Braunschweig, Germany) in 0.5 ml complete medium for 1 h. They were washed three times with complete medium and added at a concentration of 1 ϫ 10 4 cells/well in round bottomed microtiter plates (Nunc, Roskilde, Denmark). Effector cells were added at various effector:target ratios in a final volume of 200 l/well. The plates were incubated at 37°C in a humid atmosphere with 5% CO 2 for 4 h. Maximum chromium release was assessed by addition of 10% Triton-X, and spontaneous release was measured by addition of complete medium (RPMI 1640 ϩ 10% FCS) to the target cells. The culture supernatant was harvested semiautomatically with a Scatron Titertek System (Scatron, Suffolk, UK) and counted in a gamma counter (Beckmann, Heidelberg, Germany). The percentage of specific lysis was calculated as (experimental c.p.m. Ϫ spontaneous c.p.m.)/(maximum c.p.m. Ϫ spontaneous c.p.m.) ϫ 100. All determinations were made in hexaplicate. Each experiment was performed five times.
CD4/CD8 enrichment
In some experiments, enriched CD3 ϩ /CD4 ϩ and CD3 ϩ /CD8 ϩ T cells derived from the spleens of vaccinated DBA mice were obtained by removing B cells with goat anti-mouse Dynabeads (M450; Dynal, Germany), NK cells with goat anti-rat Dynabeads coated with the Pan-NK cell antibody (Clone DX5, Pharmingen), and CD8 ϩ or CD4 ϩ cells with Dynabeads coated with anti-CD8 or anti-CD4, respectively. After this procedure, the resulting cell population consisted of more than 90% of CD4 ϩ or CD8 ϩ lymphocytes and showed less than 2% of B cells, NK cells and monocytes.
TNF-␣-ELISA assay
As described above, splenocytes (5 ϫ 10 6 ) obtained from immunized donors were incubated with irradiated HOPCcells in a ratio of 5:1 (splenocytes:tumor) in a 24-well plate at 37°C. After 48 h of incubation, supernatants were harvested and tested for TNF␣ in a standardized ELISA Assay (PerSeptive Diagnostics, TiterZyme murine TNF␣, Cambridge, MA, USA). Cytokine levels were calculated with reference to standard curves which were constructed from the analysis of supernatants containing known amounts of recombinant TNF␣.
Assessment of long-term chimerism
In all surviving animals, long-term chimerism was investigated by FACS analysis determining the presence of the Lyt 1.1 (anti-CD5 MoAb, H11 86.1, Pharmingen) antigen on CD3-positive cells. This antigen exists in two different forms: Balb/c mice express the isoform Lyt 1.2, whereas DBA/2 mice are known to express the Lyt 1.1 isoform of this antigen. Animals were killed on day 180 post trans-plant, the spleens were removed and a single cell suspension was produced. Untreated animals of Balb/c served as negative controls. If the recipient mouse showed a fraction of Ͼ50% of CD3-positive cells being positive for Lyt 1.1, it was termed a long-term chimera.
Statistical analysis
Survival of animals was calculated according to the method of Kaplan and Meier. Group comparisons were made by Student's t test. The calculations were done on a PC with 'Statistica' data analysis software (StatSoft, Tulsa, OK, USA).
Results
Poor GVM effects after transfer of unmanipulated allogeneic marrow grafts and DLI
In a first set of experiments the antitumor potential of unmanipulated allogeneic MHC-identical bone marrow was evaluated. Balb/c recipients were inoculated i.p. with 1 ϫ 10 5 HOPC-1F myeloma cells. Two days later, animals were treated with TBI (7.5 Gy) followed by the transplantation of 2 ϫ 10 7 unmanipulated allogeneic BM cells derived from the MHC-identical donor DBA/2. As shown in Figure  1 mals survived the follow-up of 180 days without histological signs of myeloma relapse (MST: 71 days). The incidence of lethal acute GVHD did not differ among the experimental groups receiving BM and DLI, respectively (see Table 1 ). Donor-derived lymphocytes intended for cellular immunotherapy were tested for in vitro cytotoxicity against the myeloma cell line HOPC-1F and YAC-1 cells, the sensitive target for murine NK cells. As shown in Figure  2 , the HOPC-myeloma target could only be moderately lysed by donor-derived NK cells.
Idiotype-protein vaccination of the donor resulted in strong GvM effects
DBA donors were then treated with a vaccine consisting of the HOPC-1F myeloma-specific Ig (or the Ig control) mixed with incomplete Freund's adjuvant given i.p. three times spaced 1 week apart. Seven days after the last immunization, BM cells were harvested and transplanted into myeloma bearing recipients. As depicted in Figure 3 , transfer of marrow grafts obtained from DBA/2 mice which had been immunized with the control Ig (BM-control-P) did not elicit long-term survival. All animals died within the first 75 days post transplant (MST: 61 days). The additional adoptive transfer of 2 ϫ 10 7 splenocytes derived from the same immunized donor significantly prolonged survival (MST: 75 days vs 61 days, P Ͻ 0.05). However, no treated animal experienced long-term survival. In contrast, transplantation of marrow grafts primed with the HOPC myeloma specific Ig provides strong GVM effects. Ten of 16 animals (63%) experienced long-term survival (Ͼ180 days). This potent anti-myeloma effect did not occur with a higher incidence of lethal acute GVHD (see Table 1 ). Moreover, this anti-myeloma immune response could be significantly improved if 2 ϫ 10 7 donor immune splenocytes were administered shortly post BMT. Eighty-seven % of the treated animals (20/23) survived the observation period of 180 days (BM-HOPC vs BM-HOPC ϩ imm splenocyt P Ͻ 0.05).
Idiotype-protein vaccination did not affect GVHD
We then analyzed the survival data of each experimental group with regard to the different cause of death, ie GVHD, myeloma relapse and graft rejection. As shown in Table  1 , animals receiving immune marrow grafts and additional lymphocyte infusions did not have a significantly higher incidence of lethal GVHD. All animals succumbing to fatal acute GVHD did not exhibit any macroscopic or histological signs of myeloma relapse. 
Induction of idiotype-specific cellular immune response
To explore the cellular mechanisms of the observed antimyeloma effects, CTL were generated from splenocytes of immunized donors. Seven days after the last Id vaccination, splenocytes were harvested and stimulated in vitro with irradiated HOPC myeloma cells. As shown in Figure 4 , CTL obtained from mice treated with the myeloma specific antibody (plus IFA) demonstrated significantly higher levels of specific lysis of the HOPC-1F target compared with the group receiving IFA alone or IFA plus Ig control (P Ͻ 0.05). Similar cytolytic patterns could be observed in CTL obtain from animals transplanted with Ig 
CD8 ϩ T cells mediate an idiotype-specific cytotoxic immune response against HOPC-1F
To evaluate the role of CD4 ϩ and CD8 ϩ T cells, splenocytes obtained from DBA/2 mice receiving three i.p. injection of Ig HOPC or Ig control (spaced 1 week apart) were immunomagnetically enriched for both subpopulations and finally stimulated in vitro in the presence of irradiated HOPC myeloma cells. As shown in Figure 6 , CD8
ϩ Ig HOPCprimed CTL exhibited significantly higher cytotoxic activity against HOPC-1F target cells than Id-primed CD4 ϩ T cells.
Discussion
Although antitumor effects of allogeneic BMT and DLI are best documented in both acute leukemia and chronic myeloid leukemia, [5] [6] [7] some recently published observations also provided evidence for the existence of a GVM effect. 12 These reports are consistent with the findings of a recently published study with a larger group of patients, indicating that DLIs administered after allo-BMT were capable of inducing relevant antitumor responses in relapsed MM patients. 9 However, the close relationship of potent GVM activity with severe acute GVHD suggest that GVM effects are mainly mediated by alloreactive T cells directed against minor histocompatibility determinants present on both normal and myeloma cells, rather than by tumor-specific antigens. 9, 10 Our data clearly indicate that the basic GVM effect of unmanipulated marrow can be strongly augmented by active immunization of the donor with the myelomaspecific idiotype protein. Moreover, this effect can be enhanced by the adoptive transfer of immune splenocytes given post transplant, without aggravating severe acute GVHD.
Our studies were performed in the strain combination DBA→Balb/c; mice of these strains are MHC-identical but differ with respect to other aspects of their genetic background. The transfer of different doses of unmanipulated donor spleen cells resulted in only moderate antimyeloma effects (see Figure 1 ) with a relatively low incidence of GVHD-associated mortality. These findings correlate with the low level of cytotoxic activity of donor NK and T cells against the HOPC-1F myeloma target. Consistent with the data presented here, we previously reported moderate GVL effects against the A20 leukemia using the identical transplant model. 24 Kwak et al 22 first reported that idiotype-specific immunity elicited by active immunization of the marrow donor with myeloma Ig isolated from the recipient can be successfully transferred to the recipient. In a murine B cell lymphoma model (38C13) the same investigators show that recipients reconstituted with marrow from idiotype immune donors demonstrated protection against subsequent lethal tumor challenge. 23 In addition, modest therapeutic effects of immune marrow were observed against the 38C13 tumour (inoculated into the recipient 11 days prior to BMT), but only in combination with a booster immunization of the recipient post BMT. Our data support these observations in a mouse myeloma model and extend it to the finding that administration of donor lymphocytes obtained from idiotype-protein vaccinated donors significantly augmented the antitumor response without increasing the risk of severe GVHD. Furthermore, in id-immunized donors we were able to detect significant levels of idiotype-specific CTL activity against the HOPC myeloma target. These CTL also secrete higher amounts of TNF␣ if compared to the control groups.
However, one major drawback of this immunotherapeutic concept concerns the potential physical risk for the healthy stem cell donors. In order to circumvent this critical issue, the first experimental studies were conducted by immunizing the recipient post BMT using tumor-specific constructs. Teshima et al 25 have recently shown that vaccination of B16 melanoma-bearing recipients was ineffective following allogeneic BMT across both major and minor HLA antigens. The investigators suggested that GVHDassociated immunodeficiency prevented immune reconstitution, thereby abrogating the ability of vaccination to confer graft-versus-tumor (GVT) effects. In contrast, vaccination stimulated powerful GVT activity in recipients of T cell-depleted (TCD) allogeneic BM. TCD thus prevented the development of GVHD-associated immunodeficiency and restored the efficacy of the tumor vaccine. We are currently investigating the antitumoral effects of id vaccination conducted post allo-BMT in our experimental model.
In autologous systems, several experimental studies show evidence for id-specific T cells in mediating antimyeloma effects. 16, 26 Bogen et al 26 reported that id-specific CD4 ϩ T cells can protect against challenges with small numbers of the MOPC315 plasmocytoma. On the other hand, Ö sterborg et al 27 detected both CD4 ϩ and CD8 ϩ idiotype T cell reactivity in early stage myeloma patients following id-protein vaccination. In the current study, we were able to show that CD8 ϩ T cells are the main effector population capable of lysing HOPC myeloma targets. In contrast, Kwak et al 22 reported a CD4-mediated idiotypespecific immune response in a myeloma patient treated with allogeneic marrow graft from an HLA-identical donor immunized with the myeloma protein of the recipient. One possible explanation for the discrepant findings may rely on the different stimulator cells used in the culture systems. Whereas Kwak et al 22 generated the CD4 ϩ T cell lines in the presence of irradiated autologous feeder cells and idiotype protein, donor T cells were coincubated with irradiated MHC-class II negative but class I positive HOPC myeloma cells in our system.
Recently, Cabrera et al 28 described a case of a multiple myeloma patient relapsed after BMT, treated with lymphocyte infusions from a donor immunized with an idiotype vaccine prepared from purified tumor paraprotein. A complete clinical response was obtained without the induction of GVHD. Furthermore, the authors were able to detect significant levels of anti-idiotypic antibodies in the sera of both donor and recipient of DLI. However, whether a humoral immune response is involved in this anti-myeloma effect remained to be determined.
Taken together, our data show that active immunization of the donor with the myeloma-specific idiotype protein can generate strong GVM effects in myeloma-bearing recipients and could be additionally enhanced by the adminis-tration of immune donor spleen cells without aggravating the incidence of severe GVHD. Furthermore, by showing that CD8
ϩ T cells play a relevant role in this myelomaspecific immune response these data provide a rationale for the use of vaccination strategies and the transfer of allogeneic idiotype-specific T cells in the context of allogeneic stem cell transplantation against B cell lymphomas and myelomas.
